STAT3 and major depressive disorder: Another study by Almutabagani et al. (2023) revealed the dysregulation of the JAK2/STAT3 signaling pathway as a significant contributor to treatment-resistant depression, suggesting that targeting this inflammatory component could increase the therapeutic efficacy of existing antidepressant regimens [262].